[{"address1": "697 Burke Road", "address2": "Suite 201", "city": "Camberwell", "state": "VIC", "zip": "3124", "country": "Australia", "phone": "61 3 9092 0475", "fax": "61 3 8678 1269", "website": "https://www.tryptherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing synthetic psilocybin-related molecules in Australia, Canada, Switzerland, and the United States. The company's lead program candidate TRP-8803, a proprietary formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is also involved in the development of TRP-8802, a synthetic and oral psilocybin, currently under phase 2a clinical stager for the treatment of binge eating, as well as under phase 2 clinical stage for the treatment of fibromyalgia, and irritable bowel syndrome. The company was founded in 2019 and is based in Camberwell, Australia.", "companyOfficers": [{"maxAge": 1, "name": "Mr. Jason  Carroll", "title": "MD, CEO & Executive Director", "fiscalYear": 2024, "totalPay": 911760, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. James P. Gilligan MSIB, Ph.D.", "age": 72, "title": "President & Chief Scientific Officer", "yearBorn": 1952, "fiscalYear": 2024, "totalPay": 317780, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Christopher Leo Ntoumenopoulos", "age": 41, "title": "Executive Director", "yearBorn": 1983, "fiscalYear": 2024, "totalPay": 27862, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. William James Garner M.D.", "age": 58, "title": "Founder & MD", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 41362, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Hamish  George B.Com., C.A.", "title": "CFO & Company Secretary", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Michael H. Silverman B.Sc., F.A.C.P., FACR, M.B.A., M.D.", "age": 75, "title": "Chief Medical Officer", "yearBorn": 1949, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 4, "previousClose": 0.011, "open": 0.014, "dayLow": 0.014, "dayHigh": 0.014, "regularMarketPreviousClose": 0.011, "regularMarketOpen": 0.014, "regularMarketDayLow": 0.014, "regularMarketDayHigh": 0.014, "payoutRatio": 0.0, "volume": 10000, "regularMarketVolume": 10000, "averageVolume": 44433, "averageVolume10days": 36202, "averageDailyVolume10Day": 36202, "bid": 0.011, "ask": 0.028, "bidSize": 0, "askSize": 17154, "marketCap": 30367040, "fiftyTwoWeekLow": 0.0007, "fiftyTwoWeekHigh": 0.0385, "priceToSalesTrailing12Months": 22.879824, "fiftyDayAverage": 0.015876, "twoHundredDayAverage": 0.0164995, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 17601968, "profitMargins": 0.0, "floatShares": 778566306, "sharesOutstanding": 1438919936, "heldPercentInsiders": 0.41694, "heldPercentInstitutions": 0.0072000003, "impliedSharesOutstanding": 1897939968, "bookValue": 0.003, "priceToBook": 5.3333335, "lastFiscalYearEnd": 1719705600, "nextFiscalYearEnd": 1751241600, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -7371084, "trailingEps": -0.02, "lastSplitFactor": "1:2.5", "lastSplitDate": 1713139200, "enterpriseToRevenue": 13.262, "enterpriseToEbitda": -3.807, "52WeekChange": 0.6, "SandP52WeekChange": 0.16932249, "quoteType": "EQUITY", "currentPrice": 0.016, "recommendationKey": "none", "totalCash": 2870577, "totalCashPerShare": 0.002, "ebitda": -4624144, "totalDebt": 49795, "quickRatio": 3.694, "currentRatio": 3.865, "totalRevenue": 1327241, "debtToEquity": 1.176, "revenuePerShare": 0.003, "grossProfits": -1020004, "operatingCashflow": -7200070, "grossMargins": -0.76851, "ebitdaMargins": 0.0, "operatingMargins": -3.4901502, "financialCurrency": "AUD", "symbol": "TYPTF", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Delayed Quote", "triggerable": false, "customPriceAlertConfidence": "LOW", "corporateActions": [], "regularMarketTime": 1753401600, "exchange": "PNK", "messageBoardId": "finmb_693911067", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "marketState": "CLOSED", "regularMarketChangePercent": 45.45455, "regularMarketPrice": 0.016, "fullExchangeName": "OTC Markets OTCPK", "averageDailyVolume3Month": 44433, "fiftyTwoWeekLowChange": 0.015300001, "fiftyTwoWeekLowChangePercent": 21.857145, "fiftyTwoWeekRange": "7.0E-4 - 0.0385", "fiftyTwoWeekHighChange": -0.022499999, "fiftyTwoWeekHighChangePercent": -0.58441556, "fiftyTwoWeekChangePercent": 60.000004, "earningsTimestampStart": 1756465140, "earningsTimestampEnd": 1756987200, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -0.02, "fiftyDayAverageChange": 0.00012400001, "fiftyDayAverageChangePercent": 0.007810532, "twoHundredDayAverageChange": -0.00049949996, "twoHundredDayAverageChangePercent": -0.03027364, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "prevName": "Tryp Therapeutics Inc.", "nameChangeDate": "2025-07-25", "cryptoTradeable": false, "hasPrePostMarketData": false, "firstTradeDateMilliseconds": 1720186200000, "regularMarketChange": 0.005000001, "regularMarketDayRange": "0.014 - 0.014", "displayName": "Tryptamine Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-07-26"}]